Annual Cash & Cash Equivalents:
$118.42M+$19.31M(+19.49%)Summary
- As of today, AMRX annual cash & cash equivalents is $118.42 million, with the most recent change of +$19.31 million (+19.49%) on December 31, 2024.
- During the last 3 years, AMRX annual cash & cash equivalents has fallen by -$138.32 million (-53.88%).
- AMRX annual cash & cash equivalents is now -71.46% below its all-time high of $414.86 million, reached on December 1, 2014.
Performance
AMRX Cash and Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Cash & Cash Equivalents:
$81.19M+$15.42M(+23.44%)Summary
- As of today, AMRX quarterly cash & cash equivalents is $81.19 million, with the most recent change of +$15.42 million (+23.44%) on June 30, 2025.
- Over the past year, AMRX quarterly cash & cash equivalents has increased by +$31.56 million (+63.61%).
- AMRX quarterly cash & cash equivalents is now -82.19% below its all-time high of $455.81 million, reached on March 31, 2021.
Performance
AMRX Quarterly Cash & Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AMRX Cash and Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +19.5% | +63.6% |
| 3Y3 Years | -53.9% | -17.3% |
| 5Y5 Years | -22.5% | -69.7% |
AMRX Cash and Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | -53.9% | +236.2% | -46.3% | +130.5% |
| 5Y | 5-Year | -65.9% | +236.2% | -82.2% | +130.5% |
| All-Time | All-Time | -71.5% | +8981.3% | -82.2% | >+9999.0% |
AMRX Cash and Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $81.19M(+23.4%) |
| Mar 2025 | - | $65.77M(-44.5%) |
| Dec 2024 | $118.42M(+19.5%) | $118.42M(+51.2%) |
| Sep 2024 | - | $78.34M(+57.9%) |
| Jun 2024 | - | $49.62M(-3.9%) |
| Mar 2024 | - | $51.62M(-47.9%) |
| Dec 2023 | $99.11M(+181.3%) | $99.11M(+3.7%) |
| Sep 2023 | - | $95.61M(-16.6%) |
| Jun 2023 | - | $114.58M(-24.2%) |
| Mar 2023 | - | $151.07M(+328.8%) |
| Dec 2022 | $35.23M(-86.3%) | $35.23M(-63.3%) |
| Sep 2022 | - | $95.89M(-2.3%) |
| Jun 2022 | - | $98.18M(-54.7%) |
| Mar 2022 | - | $216.54M(-15.7%) |
| Dec 2021 | $256.74M(-26.0%) | $256.74M(-17.3%) |
| Sep 2021 | - | $310.62M(+9.7%) |
| Jun 2021 | - | $283.15M(-37.9%) |
| Mar 2021 | - | $455.81M(+31.3%) |
| Dec 2020 | $347.12M(+127.1%) | $347.12M(+22.4%) |
| Sep 2020 | - | $283.65M(+5.7%) |
| Jun 2020 | - | $268.27M(-34.1%) |
| Mar 2020 | - | $406.93M(+166.3%) |
| Dec 2019 | $152.82M(-30.1%) | $152.82M(-29.6%) |
| Sep 2019 | - | $217.06M(+280.7%) |
| Jun 2019 | - | $57.02M(-14.6%) |
| Mar 2019 | - | $66.74M(-69.5%) |
| Dec 2018 | $218.78M(+180.8%) | $218.78M(+27.1%) |
| Sep 2018 | - | $172.19M(+151.0%) |
| Jun 2018 | - | $68.59M(>+9900.0%) |
| Mar 2018 | - | $0.00(-100.0%) |
| Dec 2017 | $77.92M(-56.7%) | $77.92M(-56.7%) |
| Dec 2016 | $180.13M(-47.1%) | - |
| Dec 2016 | - | $180.13M(-22.4%) |
| Sep 2016 | - | $232.12M(-36.7%) |
| Jun 2016 | - | $366.85M(-11.0%) |
| Mar 2016 | - | $412.18M(+21.1%) |
| Dec 2015 | $340.35M(-18.0%) | $340.35M(+6.9%) |
| Sep 2015 | - | $318.40M(+67.3%) |
| Jun 2015 | - | $190.29M(+16.7%) |
| Mar 2015 | - | $163.09M(-60.7%) |
| Dec 2014 | $414.86M(+0.4%) | $414.86M(-6.3%) |
| Sep 2014 | - | $442.51M(+7.1%) |
| Jun 2014 | - | $413.03M(+5.8%) |
| Mar 2014 | - | $390.43M(-5.5%) |
| Dec 2013 | $413.13M | $413.13M(-5.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $436.65M(-3.5%) |
| Jun 2013 | - | $452.41M(+29.6%) |
| Mar 2013 | - | $349.01M(+16.8%) |
| Dec 2012 | $298.92M(-13.7%) | $298.92M(-12.0%) |
| Sep 2012 | - | $339.74M(-4.2%) |
| Jun 2012 | - | $354.48M(+3.3%) |
| Mar 2012 | - | $343.25M(-0.9%) |
| Dec 2011 | $346.41M(-0.6%) | $346.41M(-3.7%) |
| Sep 2011 | - | $359.81M(+7.2%) |
| Jun 2011 | - | $335.52M(-4.1%) |
| Mar 2011 | - | $349.96M(+0.4%) |
| Dec 2010 | $348.40M(+285.5%) | $348.40M(-2.8%) |
| Sep 2010 | - | $358.35M(+9.2%) |
| Jun 2010 | - | $328.11M(+151.7%) |
| Mar 2010 | - | $130.36M(+44.3%) |
| Dec 2009 | $90.37M(+202.9%) | $90.37M(-10.1%) |
| Sep 2009 | - | $100.53M(-2.7%) |
| Jun 2009 | - | $103.27M(+5.0%) |
| Mar 2009 | - | $98.36M(+21.2%) |
| Sep 2008 | - | $81.15M(+172.0%) |
| Dec 2006 | $29.83M(-46.8%) | $29.83M(-69.7%) |
| Dec 2005 | $56.08M(+261.7%) | - |
| Jun 2004 | - | $98.56M(+405.6%) |
| Mar 2004 | - | $19.49M(+25.7%) |
| Dec 2003 | $15.51M(+51.7%) | $15.51M(-31.0%) |
| Sep 2003 | - | $22.48M(-16.1%) |
| Jun 2003 | - | $26.79M(+138.7%) |
| Mar 2003 | - | $11.22M(+9.8%) |
| Dec 2002 | $10.22M(-71.2%) | $10.22M(-54.4%) |
| Sep 2002 | - | $22.41M(-21.1%) |
| Jun 2002 | - | $28.40M(-7.4%) |
| Mar 2002 | - | $30.68M(-13.5%) |
| Dec 2001 | $35.47M(+84.4%) | $35.47M(-15.0%) |
| Sep 2001 | - | $41.74M(-9.3%) |
| Jun 2001 | - | $46.01M(+233.1%) |
| Mar 2001 | - | $13.81M(-28.2%) |
| Dec 2000 | $19.23M(+1374.5%) | $19.23M(+136.0%) |
| Sep 2000 | - | $8.15M(-35.8%) |
| Jun 2000 | - | $12.69M(-36.3%) |
| Mar 2000 | - | $19.91M(+601.0%) |
| Mar 1999 | - | $2.84M(+117.9%) |
| Dec 1998 | $1.30M | $1.30M(+101.5%) |
| Sep 1998 | - | $647.00K(-33.9%) |
| Jun 1998 | - | $979.00K(-65.9%) |
| Mar 1998 | - | $2.87M |
FAQ
- What is Amneal Pharmaceuticals, Inc. annual cash & cash equivalents?
- What is the all-time high annual cash & cash equivalents for Amneal Pharmaceuticals, Inc.?
- What is Amneal Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
- What is Amneal Pharmaceuticals, Inc. quarterly cash & cash equivalents?
- What is the all-time high quarterly cash & cash equivalents for Amneal Pharmaceuticals, Inc.?
- What is Amneal Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
What is Amneal Pharmaceuticals, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of AMRX is $118.42M
What is the all-time high annual cash & cash equivalents for Amneal Pharmaceuticals, Inc.?
Amneal Pharmaceuticals, Inc. all-time high annual cash & cash equivalents is $414.86M
What is Amneal Pharmaceuticals, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, AMRX annual cash & cash equivalents has changed by +$19.31M (+19.49%)
What is Amneal Pharmaceuticals, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AMRX is $81.19M
What is the all-time high quarterly cash & cash equivalents for Amneal Pharmaceuticals, Inc.?
Amneal Pharmaceuticals, Inc. all-time high quarterly cash & cash equivalents is $455.81M
What is Amneal Pharmaceuticals, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, AMRX quarterly cash & cash equivalents has changed by +$31.56M (+63.61%)